CytomX Therapeutics Reports Third Quarter 2023 Financial
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC)...
Source: globenewswire.com
Probody Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Probody Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Probody Platform Today - Breaking & Trending Today
CytomX Therapeutics Presents Preclinical Profile of
- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...
Source: globenewswire.com
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
27.03.2023 - - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers ...
Source: wallstreet-online.de
MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational ...
Source: pharmiweb.com
Moderna, Inc.: Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditionsCytomX to receive $35 million upfront payment
Source: finanznachrichten.de